Consistently Safe and Effective
At 2-year follow-up for the TAXUS IV US Pivotal Trial, the incremental benefits of having received the TAXUS® stent rather than a bare metal stent continue to increase, with no apparent evidence of late catch-up.
For the TAXUS IV US Pivotal Trial data in portable document format,
click here.
| Objective: |
Demonstrate safety and superior performance of TAXUS® Express2™ Paclitaxel-Eluting Stent for treatment of de novo lesions over control. |
| Number of Patients: |
1326 enrolled: 1314 evaluable |
| Number of Sites: |
76 |
| Lesion Type: |
de novo |
| Stent Platform: |
Express2™ 16, 24, 32 mm lengths, 2.5, 3.0 and 3.5 mm diameters |
| Release Kinetics: |
Slow |
| Primary Endpoints: |
9-month TVR, superiority to control arm |
| P.I. and Co-P.I.: |
G.W. Stone, MD and S. Ellis, MD |
| Status: |
Enrollment complete |
